Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs CTKB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CTKB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)
CTKB Overall Winner
6-Pillar Tally: MXCT 0 – 5 CTKB (1 Tie)
Matrix Metrics: MXCT 2 – 6 CTKB
As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas CTKB carries 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin).
- Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs CTKB
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
CTKB
Head-to-Head Winner
Cytek Biosciences, Inc. Common Stock
$6.12
-3.16% 1D
Market Cap
$826.6M
TTM Revenue
$208M
Forward P/E
N/M
Beta / 30D Vol
0.71β · 67% Vol
Unified Composite Score
48.4
HOLD
Tech 33.0
Fund 44.0
Flow 60.0
Mom 41.1
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 5 CTKB)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
3.8x
2. Growth & Scale
CTKB
Revenue Growth (YoY)
+48.7%
+1.8%
Earnings Growth (YoY)
+0.0%
+73.5%
TTM Revenue (USD)
$34M
$208M
Market Cap
$132.2M
$826.6M
3. Profitability & Quality
CTKB
Gross Margin
81.0%
53.4%
Operating Margin
-85.5%
-22.5%
Net Profit Margin
-81.4%
-39.1%
Return on Equity (ROE)
-16.9%
-23.2%
4. Balance Sheet & Cash Flow
CTKB
Cash Generation (TTM)
-$24M
-$14M
Cash Flow Margin
-69.2%
-6.6%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$42M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CTKB
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
0.1% (<1st %ile)
Put/Call OI Skew
N/A
0.03x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
CTKB
OpEx & R&D Intensity
N/A
75.9% of Rev ($158M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (2) vs CTKB (6)| Institutional Metric | MXCT | CTKB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $826.6M | CTKB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +48.7% | +1.8% | MXCT | |
| Operating Margin (TTM) | -85.5% | -22.5% | CTKB | |
| Net Profit Margin | -81.4% | -39.1% | CTKB | |
| Return on Equity (ROE) | -16.9% | -23.2% | MXCT | |
| 52-Week Range Position | 63% ($1–$2) | 91% ($3–$6) | CTKB | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 0.71β · 67% Vol | CTKB | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 48.4 / 100 (HOLD) | CTKB | |
| Trailing 12M Revenue (USD) | $34M | $208M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 53.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · 3.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | -$14M ($42M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CTKB +16.91 pp
3M Horizon
CTKB +39.28 pp
6M Horizon
CTKB +20.89 pp
1Y Horizon
CTKB +35.76 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | CTKB Revenue | MXCT Op. Margin | CTKB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -93.7% | N/A | MXCT |
| FY2020 | $20M | $90M | -71.6% | 14.7% | CTKB |
| FY2021 | $20M | $130M | -84.3% | 7.2% | CTKB |
| FY2022 | $30M | $160M | -95.2% | -1.1% | CTKB |
| FY2023 | $20M | $190M | -247.7% | -14.4% | CTKB |
| FY2024 | $20M | $200M | -230.5% | -10.2% | CTKB |
| FY2025 | $20M | $200M | -247.6% | -20.0% | CTKB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CTKB
CONSOLIDATION
Current IV
0.1%
IV Percentile
<1st %ile
Put/Call OI Skew
0.03x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CTKB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CTKB Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
75.9% of Rev ($158M)
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs CTKB Key Questions & Quantitative Answers
As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas CTKB carries 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin). Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
CTKB leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with CTKB at +1.8% YoY revenue growth and +73.5% YoY earnings growth on $208M TTM revenue (53.4% gross margin, -22.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while CTKB shifted +122.2%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 75.9% of Rev ($158M) (0 disclosures) for CTKB.
MXCT and CTKB trade at balanced relative valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas CTKB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.8x EV/Revenue (-6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus CTKB (-23.2% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, CTKB carries 0.1% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CTKB vs MXCT · Reverse Pair
MXCT vs SGHT
· Sector Peer
MXCT vs TMCI
· Sector Peer
MXCT vs RLYB
· Sector Peer
CTKB vs SGHT
· Sector Peer
CTKB vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem